New funding for depression and Alzheimer’s research
Published: 11 December 2017
The Wellcome Trust is funding IHW researchers, led by Prof Jonathan Cavanagh, to conduct clinical trials of entirely new molecular targets for major depressive disorder and Alzheimer’s disease
Many congratulations to Jonathan Cavanagh and colleagues as the Wellcome Trust has approved funding for Phase 2 of their consortium on the neuroimmunology of mood and Alzheimer’s (NIMA). This funding, matched by industry collaborators, will allow proof of concept first stage clinical trials of entirely new molecular targets for major depressive disorder and Alzheimer’s disease.
First published: 11 December 2017